Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Alcoholic Hepatitis, Sepsis
Interventions: Vitamin C, Dextrose 5% in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Autistic Disorder
Interventions: N-Acetyl Cysteine, Placebo - sugar pill; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Osteoarthritis of the Knee
Interventions: Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Schizophrenia
Interventions: L-tetrahydropalmatine (30mg), Sugar pill; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Cystic Fibrosis
Interventions: sildenafil, placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Rheumatoid Arthritis
Interventions: JNJ-38518168, Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Heart Failure, Diuretic Resistance
Interventions: Ammonium Chloride, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bleeding, Contraceptive Device; Complications
Interventions: Tranexamic acid, Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy, Cognitive Function
Interventions: Qualia Mind, Placebo; Dietary Supplement
Lead sponsor: Neurohacker Collective; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Peripheral Arterial Disease
Interventions: Bupivacaine liposome, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Eau Claire, Wisconsin

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise; Drug · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Chronic Kidney Disease, Left Ventricular Hypertrophy
Interventions: paricalcitol, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 30
States / cities: Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 57
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 44 more

Conditions: Age-related Memory Disorders, Mood Disorders
Interventions: Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder; Dietary Supplement · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 62 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetic Nephropathy
Interventions: PF-04634817, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 65
States / cities: Little Rock, Arkansas • Azusa, California • Chula Vista, California + 47 more

Conditions: Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions: Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control); Biological · Other
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Sioux Falls, South Dakota

Conditions: Moderate-to-severe Chronic Plaque Psoriasis
Interventions: Tildrakizumab, Placebo, Etanercept; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 6 Years to 215 Months
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 5
States / cities: Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more

Conditions: Alcohol Drinking, Marijuana
Interventions: THC 7.2%, THC 3.1%, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 44 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Mild Cognitive Impairment (MCI)
Interventions: EVOO-phenolics dietary supplement, Placebo; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cytomegalovirus Infection
Interventions: Brincidofovir, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more

Conditions: Alzheimer's Disease
Interventions: ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b; Drug · Other
Lead sponsor: AZTherapies, Inc.; Industry
Eligibility: 55 Years to 79 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 69
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more

Conditions: Blood Pressure, Inflammation
Interventions: Recommended sodium and low fructose diet, High sodium and low fructose diet, High sodium and high fructose diet; Dietary Supplement
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: LY3461767, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina

Conditions: Type 2 Diabetes, Microalbuminuria
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

A Study of N-Acetyl Cysteine in Children With Autism

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects

Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population

A Study of Loco-Regional Liposomal Bupivacaine Injection

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Marijuana's Impact on Alcohol Motivation and Consumption

Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

The Impact of Sodium and Fructose on Blood Pressure and Inflammation

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Use of Sitagliptin to Decrease Microalbuminuria